Viruses can use exosomes to make themselves more infectious. For example, exosomes can carry transcription factors, which are proteins that help viruses make more copies of themselves (Subra et al., 2007).

Exosomes and viral infection can deliver their molecules, such as proteins, RNA, or DNA, to other cells and alter their gene expression and function. Their molecules have a key role for attaching to the cell membrane (for example, tetraspanins are a family of proteins that are involved in cell adhesion and signaling) (Andreu and Yáñez-Mó, 2014). In addition, the cell affinity to bind viral protein are mostly determined by its secreted exosome. Furthermore, the affinity of the cell to bind viral protein is largely influenced by the type and amount of exosome that it secretes. However, this phenomenon has only been investigated in vitro studies experimentally (Urbanelli et al., 2019) and it could be an interesting topic for future research. Therefore, there is a bidirectional interaction between viruses and exosomes in the human body that could affect the occurrence or development of various virus-related diseases (Fig. 2).

The initial symptoms of SARS-CoV-2 infection are often mild and resemble those of other respiratory virus diseases, such as dry cough, tiredness, sore throat, anorexia, high fever, myalgia, and nasal congestion (Ashour et al., 2020; Krajewska et al., 2020; Mohammadi et al., 2022; Sheykhhasan et al., 2020). However, these symptoms may worsen over time and cause respiratory distress that requires hospitalization (Al Balushi et al., 2020). It has been estimated that about 80% of symptomatic patients do not need medical assistance or hospitalization, but the mortality rate among patients admitted to the ICU varies from 39% to 72% (Verity et al., 2020). Furthermore, the COVID-19 virus particles can impair the function of sensory receptor cells (blocking olfaction) by binding to the angiotensin-converting enzyme 2 or ACE2 receptors, which are highly expressed in the olfactory epithelial cells and oral mucosa (Fotuhi et al., 2020).

As expected, old adults with COVID-19 infection tend to have higher levels of production of cytokines, including IL-2, IL-6, IL-7, IL-10, IP-10, and TNFα, than young or healthy adults (Palanques-Pastor et al., 2020; Zhong et al., 2020). Furthermore, excessive levels of pro-inflammatory cytokines can cause higher blood viscosity and fatal thromboembolism in some elderly adults with COVID-19 infection (Soy et al., 2020). In these regards, multiple organ dysfunction may result from hyper-activation of pro-inflammatory markers and vascular damage in the heart, brain, kidney, and liver. Besides, the COVID-19-infected patients experience neurological symptoms such as anosmia or stroke (Ahmad and Rathore, 2020).

Several molecular tests have been approved for in vitro diagnostics of COVID-19, such as RT-PCR (Allan et al., 2020; Wang et al., 2020), Next-Generation Sequencing (NGS) (Chen et al., 2020), and loop-mediated isothermal amplification (LAMP) (Jiang et al., 2020). RT-PCR can detect high levels of SARS-CoV-2 viral RNA in patients with asymptomatic and pre-symptomatic SARS-CoV-2 infections (Nile et al., 2020).

SARS-CoV-2 antibodies that recognize prior infection and immunity are useful for ongoing surveillance, epidemiologic/vaccine studies, and estimating the risk of health care workers (Cheng et al., 2020; Huang et al., 2020; Krammer and Simon, 2020). Specifically, SARS-CoV-2 IgG appears ~10 days post-infection and peaks at day 49, while IgM antibodies appear ~7 days after symptom onset and peak at day 28 (Huang et al., 2020).

It is known that the immune system is a natural defense mechanism that fights against invasive microbial infections. Exosomes mediate various types of biological processes during micro-organism infections and stimulate immune responses (Chitra and Harikumar, 2018). Briefly, immuno-exosomes are formed by the budding of sub-cellular endosomal membranes inward from immune effector cells (Wu et al., 2019) and delivered extracellularly to various cell types, such as T and B cells, dendritic cells (DCs), platelets, NK cells, mast cells, and epithelial cells (Admyre et al., 2007). Recent studies suggested that exosomes can be a promising specimen for the detection of COVID-19. SARS-CoV-2-infected cells can produce exosomes with more virus particles that these exosomes that transport viral and self-antigens, triggering the host immune response (Wan et al., 2020). It was proved that exosomes are important not only for sorting ACE2, but also for sorting proteins, miRNAs, and other cargo that can be transmitted to healthy cells like other viruses (Gunasekaran et al., 2017). Exosomes also alter the cargo of proteins involved in the pro-inflammatory, coagulopathy, and endothelial damage. Furthermore, it was reported that some exosomes can transfer ACE2 to receipt cells and facilitate the SARS-CoV2 internalization and infection (Wang et al., 2020), suggesting a link between exosomes and COVID-19 diagnosis (Hassanpour et al., 2020). The treatment of COVID-19 infection with antibody-mediated exosomes involves targeting the spike protein with monoclonal antibodies and internalizing them into the endosomes, then fusing the membranes to transfer genetic materials and prevent viral replication (Salvatori et al., 2020; Lee et al., 2021). It has been shown that exosomes and other extracellular vesicles (EVs) are released by infected cells and can adjust the immune response (Gurunathan et al., 2021). Barberis et al., 2021 found that SARS-CoV-2 infection changes exosome content and affects their role in disease progression and their potential application as biomarkers of disease severity (Barberis et al., 2021). For example, Fujita et al. (2021) found three potential early COVID-19 biomarkers and found that COPB2 extracellular vesicle had the optimal predictive value for the severe deterioration of COVID-19 patients (Fujita et al., 2021). It has been demonstrated that exosomes produced by SARS-CoV-2-infected cells contain specific proteins, such as fibrinogen, complement C1r subcomponent, and serum amyloid P-component, that act as important disease biomarkers (Barberis et al., 2021). Moreover, exosomes from virus-infected cells can release cytokines and chemokines from human monocytes and/or airway epithelial cells, which then trigger an innate immune response (Chahar et al., 2018).

Exosomes can also enhance antiviral responses in infected cells by various mechanisms (Rezabakhsh et al., 2022). For example, the secretion and synthesis of interferons can be increased by the transfer of interferon-stimulated genes (ISGs) through exosomes (Yao et al., 2018). Studies indicate that MSC-Exo contains high amounts of anti-inflammatory cytokines such as IL-10 and TGF-β (Rezabakhsh et al., 2022). MSC-Exo can produce specific growth factors, including vascular endothelial growth factor and basic fibroblast growth factor, that can restore the function of the alveolar-blood barrier and limit the infiltration of immune cells into the infected areas (Rezabakhsh et al., 2022). Exosome has cytoprotective properties against viral infection and high levels of antibacterial components, according to various studies. Exosome may have antibacterial effects by inhibiting bacterial growth and promoting phagocytosis in local immune cells (Russell et al., 2020). It appears that intranasal administration of exosome at the early stages of COVID-19 may reduce the replication and dissemination of certain SARS-CoV-2 strains into lower regions (Barberis et al., 2021). In fact, intranasal administration of exosomes is a more effective route for treating pulmonary disease and neurodegenerative disorders, as this way delivers more exosomes to the target site, while intravenous injection reduces the number of exosomes significantly within a few hours (Moss et al., 2021). However, intravenous administration of purified exosomes may reduce the need for invasive mechanical ventilation for respiratory failure in those patients with severe COVID-19 (Tsuchiya et al., 2020).

In an earlier study, exosomes derived from BM-MSCs were safe in improving pneumonia parameters, attenuating the cytokine storm, and restoring COVID-19 patients’ immunity (Sengupta et al., 2020). However, recent reports suggested further clinical research on exosomes derived from MSCs and ADSCs for the treatment of COVID-19 patients (Rogers et al., 2020; Mahida et al., 2020; Worthington and Hagood, 2020).

Exosomes are small vesicles that can carry substances from infected cells to uninfected cells and facilitate the transmission of HBV. Most liver cells, including hepatocytes and Kupffer cells, have the ability to release or be targeted by exosomes (Jiao et al., 2021).

Ramakrishnaiah et al. (2013) were the first to demonstrate in 2013 that exosomes from HCV-infected hepatoma cells could contain viral particles (Ramakrishnaiah et al., 2013). On this subject, exosome markers (such as the tetraspanin CD63) have a crucial role in the formation and distribution of HBV particles (Ninomiya et al., 2021). In fact, exosomes act as a protective shield for the viral components to evade the immune system (Aydin et al., 2021). In this respect, exosomes can shield HBV particles from being destroyed. This, in turn, facilitates the infection/dysfunction of hepatocytes and immune cells such as NK cells (Yang et al., 2017). One of the mechanisms for weakening the body’s ability to fight viruses is that non-coding RNA (e.g., miR-155, miR-221, and miR-192) present in HBV-infected exosomes can directly target the human IL-21 gene and subsequently impair the function of T cells, which are essential for antiviral immunity (Enomoto et al., 2017). Wu et al. (2023) demonstrated the presence of a significant mechanism involving the hepatitis B virus (surface antigen) and Na+-taurocholate (co-transporting polypeptide) on the surface of exosomes derived from HBV-expressing cells (Wu et al., 2023). Exosome-encapsulated HBV was able to initiate infection in susceptible cells, demonstrating its capability for transmission. However, non-permissive cells exhibited a significantly lower efficiency in absorbing exosomal HBV (Wu et al., 2023). In a study conducted by Zhang et al. (2023), it was discovered that liver fibrosis is exacerbated by exosomal miR-222 derived from HBV-infected hepatocytes, which occurs through the blockade of the transferrin receptor and the induction of ferroptosis (Zhang et al., 2023). Recent findings reveal that exosomes derived from serum infected with HBV have been found to diminish NK cell function. These exosomes adversely affect various aspects of NK cell activity, such as interferon (IFN) production, lytic function, proliferation, and viability. Moreover, they also impede cellular responses to poly (I:C) stimulation (Yang et al., 2017). In HBV transgenic mice, exosomes produced by HBV hindered the immune response and expedited the progression of chronic hepatitis B (CHB). The presence of HBV-derived exosomes resulted in the inhibition of HBV-replicating cell elimination in HBV-infected mice, thereby exacerbating the course of the disease. These findings indicate that HBV infection leads to alterations in exosomal contents, which have a significant impact on disease progression (Liu et al., 2023). In recent years, there have been significant advancements in the discovery of diagnostic and prognostic biomarkers for various types of viral infection (Bodaghi et al., 2023; Tribolet et al., 2020; Hasham et al., 2020; Kramvis et al., 2022). Notably, microRNAs, lnc RNAs, and cRNAs in exosomes have emerged as promising biomarkers. A recent study explored the possibility of serum exosomal adenosylhomocysteinase as a novel predictive biomarker for (HBV-induced) liver cirrhosis (Tong et al., 2021a), sheding light on the importance of identifying and utilizing new biomarkers in the diagnosis and prognosis of diseases. In individuals with chronic hepatitis B who have not undergone prior treatment, there exists a favorable correlation between serum exosome HBV-miR-3 and markers such as HBV DNA, pgRNA, and notably, hepatitis B e antigen (Gan et al., 2022). Moreover, the utilization of exosomal HBV-DNA has been identified as beneficial for individuals exhibiting a high level of suspicion for HBV infection, despite yielding negative results in serum HBV-DNA tests (Xu et al., 2023). The serum exosomal AHCY level has been identified as a potential unique predictive biomarker in patients with HBV-LC. Its presence holds significant implications for the prognosis of HBV-LC patients (Tong et al., 2021a). Furthermore, research findings have indicated the potential of exosomes in treating HBV infection by inhibiting HBV transcription and replication (Liu et al., 2023).

HCV infection stimulates increased production of miR-155 in liver tissues, leading to abnormal growth of liver cells and the formation of tumors (Zhang et al., 2012).

According to recent findings, it has been observed that RNA present in exosomes infected with HCV has the ability to stimulate immune cells, particularly monocytes, to increase the production of Galactin-9 (gal-9). Gal-9 is a molecule that binds to T cells and facilitates the persistence of HCV infection within the body (Mengshol et al., 2010). The above discovery holds great potential in the early diagnosis and treatment of HCV infection. Adenosylhomocysteinase, a crucial enzyme in transmethylation reactions and a component of serum exosomal, emerges as a promising prognostic biomarker for liver cirrhosis induced by HBV (Tong et al., 2021b). In addition, it has been observed that individuals with chronic HCV exhibit elevated levels of CD81 protein in their serum exosomes. This finding suggests a potential link between CD81 protein, inflammation, and the severity of fibrosis (Welker et al., 2012).

Interferon-α (IFN-α) holds significant importance in HBV treatment strategies as it possesses inhibitory potential against the hepatitis B surface antigen. As a result, it is widely considered a valuable candidate for HBV therapy. Furthermore, the utilization of exosomes loaded with IFN-α has emerged as a promising approach to sustain the drug's efficacy. These exosomes facilitate the delivery of IFN-α from healthy liver cells to the infected ones, aiding in the continuity of the treatment process (Wu et al., 2021). exosomes have demonstrated effective capabilities in antigen presentation for recombinant vaccines. A notable example is the utilization of exosomes derived from CD4+ T cells, which have shown the ability to enhance B cell activity and improve the effectiveness of the HBsAg vaccine (Lu et al., 2019; Jesus et al., 2018). Pradhan et al. (2022) discovered a significant increase in miR-375 levels within exosomes isolated from individuals with cirrhosis and hepatocellular carcinoma (HCC). Further evidence supporting the involvement of miR-375 in HCV pathogenesis comes from observations of inhibited cell migration and proliferation in HCV-infected cells when miR-375 is depleted. Additionally, exosomes derived from HCV-infected cells have the ability to release miR-375, which can then be transferred to uninfected Huh7.5 cells, resulting in enhanced proliferation and migration capabilities (Pradhan et al., 2022).

Moreover, the weakened immune system in immunosuppressed people may make it easier for viruses to infect different parts of the body, such as the nervous system (Kennedy, 2021). Of this, Zika virus (ZIKV) was first identified as a yellow fever virus in the Zika Forest of Uganda. In 2015, ZIKV reemerged as a potential cause of severe developmental problems in the central nervous system (CNS) (Dick et al., 1952). ZIKV can impair the formation of new neurons in the CNS. For example, in an experimental model, Zika virus caused neuronal death and small brain size by activating a stress-induced response to misfolded proteins (Gladwyn-Ng et al., 2018). Especially, it is essential to monitor pregnant women who were exposed to ZIKV to detect any possible neurological problems early (Marbán-Castro et al., 2021). On the other hand, ZIKV infection was found to cause autonomic neuropathy and meningoencephalitis complications in the adult nervous system (Acosta-Ampudia et al., 2018).

Exosomes can pass through the BBB, which means they can carry viral signals to the brain. This is important for viral infection of the nervous system. By studying exosomes from infected cells, researchers found that exosomes are associated with non-structural protein 1 (NS1), which is a viral toxin (El Safadi et al., 2022). Moreover, ZIKV infections can affect the miRNAs in exosomes from host neural cells (such as miR-4792), which are involved in biological processes like oxidative stress (Tabari et al., 2020). Neutral Sphingomyelinase SMPD3is a crucial molecule for exosome production or release in neural cells. Zhou et al. (2019) reported that ZIKV can change the activity of this molecule, which may help it to spread through exosomes and cause severe neuronal damage (Zhou et al., 2019). Zika virus-infected cells secrete exosomes with specific viral protein profiles, and more exosomes are released during ZIKV infection than in noninfected cells. Also, the exosome release with Zika viral genomes is controlled by CD63, a tetraspanin that is abundant in exosomes (York et al., 2021).

Among viruses, the most widely recognized retrovirus is HIV-1 (Lu et al., 2011; Poondla et al., 2023; Sheykhhasan et al., 2021a). Exosomes play a role in facilitating the transmission of HIV-related proteins to target cells, thereby accelerating the spread of infection by rendering recipient cells more susceptible to HIV (Arenaccio et al., 2015). Specifically, the protein Nef is transmitted via exosomes, which subsequently activate cells and heighten their vulnerability to HIV infection upon reaching latent cells (Arenaccio et al., 2015). Furthermore, Nef possesses the capacity to inhibit the production of CD4+ exosomes by T cells, thereby diminishing the immune cells’ capability to identify viruses (Lu et al., 2019). Previous studies have demonstrated that the presence of Nef in exosomes leads to the apoptosis or senescence of CD4+ T cells (Lenassi et al., 2010; Arenaccio et al., 2014). Based on Schaefer et al. (2008), it has been observed that macrophages release exosomes containing Nef, which hinder T cell function by breaking down MHC-I and CD4+ molecules through a beta-COP-dependent mechanism (Schaefer et al., 2008). Furthermore, it has been observed that Nef+ exosomes possess the capability to hinder the adaptive immune response by decreasing the production of IgA and IgG in B cells. This evasion mechanism employed by the virus allows it to evade the humoral immune response, as documented (Xu et al., 2009). In addition, Dubrovsky et al. (2022) conducted research revealing that when human monocyte-derived macrophages, generated from monocytes pre-treated with extracellular vesicles containing the HIV-1 protein Nef (exNef), were stimulated by lipopolysaccharide, they exhibited an increased release of pro-inflammatory cytokines (Dubrovsky et al., 2022; Rezaie et al., 2021). Also, it was observed that the quantity of plasma extracellular vesicles significantly increased during the onset of an acute infection, correlating with the viral load. Following the simian immunodeficiency virus (SIV) or macaque model of HIV infection, specific microRNAs such as miR-181a, miR-342-3p, and miR-29a, which are present in extracellular vesicles, exhibited a decrease and remained downregulated during the latency phase (Huang et al., 2023).

Exosomes released from HIV-1-infected cells carry viral receptors, potentially rendering target cells more vulnerable to infection. Notably, the transmission of CCR5 to CCR5 null cells through exosomes derived from CCR5+ ovary cells and peripheral blood mononuclear cells (PBMNCs) has been observed, resulting in an increased susceptibility to HIV-1 infection (Mack et al., 2000). According to research conducted by Rozmyslowicz et al. (2003), exosomes produced by megakaryocytes and platelets contain HIV co-receptors CXCR4. This presence of CXCR4 makes CXCR4-null cells more susceptible to X4-HIV infection (Rozmyslowicz et al., 2003). These findings indicate that exosomes contribute to the transmission of viral receptors, potentially putting recipient cells at risk of HIV infection. However, the impact of these findings on animal models remains uncertain (Rezaie et al., 2021).

Furthermore, it has been observed that viral nucleic acids can be packaged into exosomes, leading to the transfer of the viral genome to healthy cells and consequently enhancing the rate of infection. For example, exosomes derived from HIV-infected cells have been found to transmit the specific transactivation response element (TAR) RNA (Zhou et al., 2019). TAR RNA, located at the 5' end of HIV transcript copies, interacts with the Tat protein to generate viral RNAs. The presence of TAR-RNA in exosomes can suppress a Bcl-2 interacting protein, finally promoting viral development and resistance to apoptosis (Zhou et al., 2019; Marbán-Castro et al., 2021). In fact, TAR plays a crucial role in preventing apoptosis, thereby facilitating the production of the virus within infected cells (Tabari et al., 2020).

Exosomes derived from infected cells can potentially exert an antiviral influence. Specifically, exosomes from infected cells contain APOBEC3G molecules, which serve as antiviral proteins that impede virus formation. These proteins effectively convert cytosine residues to uracil in the negative strand of viral DNA during reverse transcription. Notably, the exclusion of Vif, an opposing viral protein, from exosomes enhances this advantageous trait (Khatua et al., 2009). Additionally, the exosomes released by infected cells contain cGAMP, a molecule capable of triggering the production of interferon and activating innate immune responses. This, in turn, leads to the initiation of an antiviral defense mechanism (Bridgeman et al., 2015; Gentili et al., 2015). Based on the research conducted by Bernard et al., it has been found that certain HIV-related miRNAs, such as miRNA-88 and miRNA-99, play a role in activating the endosomal NFkB and TLR8 signaling pathways. These signaling pathways, in turn, stimulate the immune system’s response to combat HIV by inducing the production of TNF-α in macrophages (Bernard et al., 2014). Based on research findings, it has been observed that when NLRP3, a specific protein, is silenced in microglia, it leads to the production of Tat-microglia-derived-EVs. These EVs have shown to possess protective effects on various aspects of neuronal function, including miniature excitatory postsynaptic currents, spine density, and synaptic proteins. While the role of NLRP3 in inflammation is widely acknowledged, an intriguing discovery has suggested that targeting NLRP3 could be beneficial in treating HIV-associated neurological disorders, as it plays a role in EV-mediated neuronal injury (Muthukumar et al., 2022).

The potential of exosome-derived miRNA-21 as a predictive biomarker was proposed in studying HIV-1-infected elite controllers’ patients. This proposition arose from the observation that exosomes obtained from a specific subgroup of these patients demonstrated a decrease in miRNA-21 levels. This decrease correlated with the progression of HIV infection, as reflected by a decline in T CD4 lymphocyte count (Ruiz-de-León et al., 2019).

Kodidela et al. (2018) conducted a proteome analysis on exosomes derived from the plasma of HIV-positive individuals who were frequent smokers, drinkers, or both. Their findings revealed different concentrations of hemopexin, alpha-2-macroglobulin, properdin, IL-8, and IL-10 in the exosomes of the HIV-positive groups who smoked and drank. These altered exosomal proteins and chemokines hold potential as biomarkers for identifying HIV-positive individuals with substance dependence (Kodidela et al., 2018; Kodidela et al., 2020). A research study conducted by Poveda et al. (2023) demonstrated the significant effectiveness of IL-18 levels in distinguishing individuals with HIV from uninfected controls. It also proved to be a reliable differentiator between elite controllers and those receiving antiretroviral therapy (ART), as well as between individuals with durable control and those with transitory control (Poveda et al., 2023). Exosomes have been discovered to carry immunologically activating proteins and contribute to oxidative stress. They also exhibit immunomodulatory effects on myeloid cells, and in HIV patients receiving antiretroviral therapy (ART), they may potentially have pro-inflammatory and redox effects during pathogenesis (Chettimada et al., 2018). Marques de Menezes’ study revealed a correlation between EVs exhibiting activation of monocyte and neural markers and HIV-related cognitive impairment. This discovery suggests that specific subsets of EVs could serve as novel biomarkers for assessing brain damage in HIV infection. Furthermore, the study highlighted a potential interaction between circulating platelet EV levels and monocyte activation, indicating a previously unrecognized aspect in the pathophysiology of HIV-induced cognitive impairment (de Menezes et al., 2022). Based on research findings, it has been observed that in individuals with HIV who are using cART (combination antiretroviral therapy), there is a connection between extracellular vesicles expressing monocyte markers and carotid intima-media thickness (cIMT). Moreover, EV fractions derived from HIV-positive individuals have been found to induce endothelial cell death through necrotic pathways. These discoveries suggest that EVs could potentially serve as both indicators and therapeutic targets in understanding the development of cardiovascular disease (CVD) within the context of treated HIV infection (Menezes et al., 2022).

Exosomes come from inside the body, so they can be used for therapeutic purposes such as delivering proteins, peptides, RNA, genes, vaccines, and immunotherapy. The main challenge for using exosomes is to find ways to isolate and purify them. Different uses need different levels of recovery and specificity. Standard methods are needed for separating and purifying exosomes. The methods should be fast, efficient, specific, viable, and reproducible. Exosomes from inside the body are stable in the blood and can avoid being eaten by phagocytes and macrophages. Exosomes only last in the body for 2 to 20 min, though. The existing content inside exosomes limits how much external drug can be loaded, making it less effective (Chaudhari et al., 2022).

Various techniques have been employed to load drugs into exosomes, such as preloading and post-loading; however, these techniques require further optimization to achieve optimal outcomes. Large-scale production of exosomes entails serious concerns regarding aspects such as purity, potency, scalability, variability, and repeatability. It will entail considerable expenses to produce on a massive scale and introduce it to clinical settings. To elucidate how to utilize exosomes in biomedical applications, the function of exosomes must be investigated thoroughly (Chaudhari et al., 2022).

Exosomes that are loaded with drugs or not may have different effects and behaviors in living organisms. The pharmacokinetics and pharmacodynamics of therapeutic exosomes, which are the processes of how the drug moves and acts in the body, may differ from those of endogenous exosomes, which are the ones that are naturally present in the body (Chaudhari et al., 2022). The influence of exosomes on the exposure of drugs in vivo, which is the amount and duration of drug presence in the body, has to be extensively evaluated through long-term safety and toxicity studies. The impact of drug-loaded exosomes on the recipient cells, which are the cells that take up the exosomes, the absorption process, which is how the exosomes enter the cells, the intracellular and extracellular behavior, which is how the exosomes act inside and outside the cells, and the drug unloading mechanisms, which are how the exosomes release the drug, can all be studied using in vitro models, which are experiments done outside living organisms. The PK of therapeutic exosomes can be further investigated using additional in vivo methods, which are experiments done inside living organisms, and physiologically based pharmacokinetic models, which are mathematical models that simulate how the body works (Chaudhari et al., 2022). The creation of artificial exosomes is a promising solution for translational medicine, which is the process of applying research findings to clinical practice, because it can address the critical issues listed above and result in homogeneous exosomes, which are exosomes that have consistent properties and quality. Exosome-based biological applications have a bright future as synthetic exosomes are currently being developed (Chaudhari et al., 2022).